Resolute cardiovascular data

In the open-label, single-arm Japanese RESOLUTE Japan trial in 100 patients with <=2 de novo native coronary lesions with 50-100% diameter stenosis, reference vessel diameters of 2.5-3.5 mm and lesion lengths of <=27 mm, the Resolute stent was superior to historical data for patients receiving the Taxus paclitaxel-eluting coronary stent in the Phase II/III ENDEAVOR IV trial on the primary endpoint of in-stent late lumen loss at 8 months (0.13 mm vs. 0.42 mm, p<0.0001). The rate of target lesion failure (TLF) was 4% in RESOLUTE and there were no instances of stent thrombosis. Data were presented at the Japanese Association of Cardiovascular Intervention and Therapeutics meeting in Osaka. ...